{'fraction_non_alphanumeric': 0.03426791277258567, 'fraction_numerical': 0.017133956386292833, 'mean_word_length': 5.628865979381444, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Lipoxin A4 inhibited hepatocyte growth factor‐induced invasion of human hepatoma cells

Aim:  Inflammation is a critical component of tumor progression. Lipoxin A4 (LXA4) has been approved for potent anti‐inflammatory properties. Recently, it was reported that LXA4 repressed the expression and activity of cyclooxygenase‐2 (COX‐2), which is essential for invasion. However, there are few reports dealing with its effects on cancer. To explore whether LXA4 regulate invasion, the effects of LXA4 and its receptor agonist BML‐111 on hepatocyte growth factor (HGF)‐induced invasion of hepatoma cells and the possible mechanisms were researched.